The dying person’s need for healing

Matthias Girke

Last update: 17.09.2015

The problematic term “therapia minima” (palliative care) leads us to the question of physicians’ engagement in one of the most important moments in a human biography. Certainly, many medicines used in the preceding treatment period can be discontinued. Nevertheless, it is important to pay attention to the current need for treatment, and medicines that support human beings’ ability to overcome illness should still be administered in this phase.

After all—all ability to overcome illness, however small, is in a broader sense health-giving, and continues to require support. Of course, one would adjust a mistletoe treatment, for example, to fit the current situation and change the rhythm of the applications and concentrations. Eventually, the soul-spirit being will loosen itself more and more from the metabolic-limb system and will no longer respond to a higher-dosed Viscum medicine there. Many cancer patients explicitly request the continuation of mistletoe therapy in advanced stages of the illness, despite the injections. Pain therapy will also need to be adjusted, as the need for morphine, for example, often decreases in the period before death. Previously required doses should not simply be continued, unchanged.

Research news

Case series: Topical application of Viscum album extract in keratinocyte carcinomas shows remissions 
A retrospective case series examined the safety and clinical effects of topical application of 10% lipophilic Viscum album extract (VALE) in individual cases of cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC) and actinic keratosis (AK). The study population consisted of 55 patients with 74 skin lesions. Risk factors, concomitant therapies and diseases, adverse drug reactions to VALE and other relevant information were documented. As a result, the clinical response rate was 78% for cSCC, 70% for BCC and 71% for AK. The complete remission rates for individual lesions were 56% for cSCC, 35% for BCC and 15% for AK. Overall, the results suggest that VALE is a safe and tolerable extract, and complete and partial remissions of ceratinocyte carcinomas were observed with its use. The article is published in Complementary Medicine Research
https://doi.org/10.1159/000537979.


Further information on Anthroposophic Medicine